No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Context Therapeutics Inc. (CNTX) stock was $0.34 as of Oct 5, 2026, 4:00 PM EDT, up 8.65% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -69.2% · 3-year avg -36.3%/yr
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Biotechnology · Philadelphia, PA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.09
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.15
vs Estimate
$-0.09
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CNTX | $30.92M | $0.34 | +8.65% | -69.24% | N/A | N/A | N/A |
| 2CRVO | $30.65M | $3.31 | +9.60% | -61.36% | -38.25% | -53.96% | vs CNTX |
| 3BDMD | $31.36M | $0.74 | -1.09% | -63.41% | N/A | N/A | vs CNTX |
| 4EUDA | $32.31M | $17.30 | +0.37% | -61.04% | N/A | N/A | vs CNTX |
| 5BYSI | $32.32M | $0.79 | -0.17% | -54.91% | -44.30% | N/A | vs CNTX |
| 6ATYR | $28.43M | $0.29 | +0.97% | -62.41% | N/A | N/A | vs CNTX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 8 analysts
Average Price Target
$4.03
+1098.4% upside
Low
$2.00
Current
$0.34
High
$5.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.13 | $-0.11 | $-0.08 | 5 |
| Quarter ending Dec 2026 | $-0.14 | $-0.11 | $-0.10 | 5 |
| Quarter ending Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 3 |
| Quarter ending Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.53 | $-0.46 | $-0.40 | 7 |
| FY 2027 | $-0.46 | $-0.43 | $-0.39 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.00M | $2.00M | $2.00M | 8 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
